Mirati Therapeutics (MRTX) is Reiterated by Wedbush to Outperform, Lowers Price Target to $ 27

Mirati Therapeutics (MRTX) was Reiterated by Wedbush to “Outperform” while Lowering the Price Target of the company shares to $ 27 from a previous price target of $29 . Wedbush advised their investors in a research report released on Jun 6, 2016.

Many Wall Street Analysts have commented on Mirati Therapeutics. Mirati Therapeutics was Downgraded by Jefferies to ” Hold” on Jun 6, 2016. Shares were Reiterated by Wedbush on May 24, 2016 to “Outperform” and Lowered the Price Target to $ 29 from a previous price target of $41 .Shares were Reiterated by Wedbush on May 9, 2016 to “Outperform” and Lowered the Price Target to $ 41 from a previous price target of $45 .

Mirati Therapeutics closed down -0.73 points or -3.83% at $18.35 with 1,27,315 shares getting traded on Friday. Post opening the session at $19.01, the shares hit an intraday low of $18.02 and an intraday high of $19.2523 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Jan 19, 2016, Mark J Gergen (Executive VP, COO) sold 10,000 shares at $25.92 per share price. According to the SEC, on May 27, 2015, Jamie Christensen (SVP & Chief Scientific Officer) sold 4,750 shares at $28.07 per share price.

Mirati Therapeutics

Leave a Reply

Mirati Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Mirati Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.